Synthekine Inc., an engineered cytokine therapeutics company, today announced positive initial results from a Phase 1a/1b clinical trial of STK-012 in first-line, PD-L1 negative nonsquamous (NSQ) ...

From a financial perspective, Sanlorenzo is a profitable firm and has growing revenues. In addition, it has a 47% ...

If it seems like bitcoin prices react particularly negatively to falling stocks, but don't do a whole lot when stocks fly higher, you're not imagining it.

Why fantasy managers shouldn't be surprised if Marcus Mariota is playable, A.J. Brown comes alive and Kyren Williams carries ...

Q3 2025 Management View CEO Victor Coleman reported "another solid quarter of execution" and highlighted that Hudson Pacific is tracking for its "strongest office leasing year since 2019," with over ...

Discover TOI’s Q3 2025 earnings: record pharmacy growth, first EBITDA-positive month, stronger 2025 outlook, and AI efficiencies.

Granted FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCCData from a Phase ...

-- STK-012 is an <ALPHA>/<BETA> biased IL-2 designed to specifically stimulate antigen activated T cells -- Results from an ongoing Phase 1a/1b to be presented at SITC -- Company will also present new ...

Our experts dive in to the lines and player props that offer value for Week 10, and share their tips and bets.

The city of Center Line has withdrawn from a federally-funded public safety training program following pushback from ...

Kim Kardashian expressed concerns that 'All's Fair' wouldn't land with critics — and she wouldn't pass the bar exam on the ...